BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27684983)

  • 1. Automated Bright-Field Dual-Color In Situ Hybridization for MDM2: Interobserver Reproducibility and Correlation With Fluorescence In Situ Hybridization in a Series of Soft Tissue Consults.
    Zhang G; Lanigan CP; Goldblum JR; Tubbs RR; Downs-Kelly E
    Arch Pathol Lab Med; 2016 Oct; 140(10):1111-5. PubMed ID: 27684983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms.
    Weaver J; Downs-Kelly E; Goldblum JR; Turner S; Kulkarni S; Tubbs RR; Rubin BP; Skacel M
    Mod Pathol; 2008 Aug; 21(8):943-9. PubMed ID: 18500263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of MDM2/CDK4 amplification in lipomatous soft tissue tumors from formalin-fixed, paraffin-embedded tissue: comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH).
    Creytens D; van Gorp J; Ferdinande L; Speel EJ; Libbrecht L
    Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):126-33. PubMed ID: 25679065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas.
    Zhang W; McElhinny A; Nielsen A; Wang M; Miller M; Singh S; Rueger R; Rubin BP; Wang Z; Tubbs RR; Nagle RB; Roche P; Wu P; Pestic-Dragovich L
    Appl Immunohistochem Mol Morphol; 2011 Jan; 19(1):54-61. PubMed ID: 20881839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR.
    Sirvent N; Coindre JM; Maire G; Hostein I; Keslair F; Guillou L; Ranchere-Vince D; Terrier P; Pedeutour F
    Am J Surg Pathol; 2007 Oct; 31(10):1476-89. PubMed ID: 17895748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor.
    Kashima T; Halai D; Ye H; Hing SN; Delaney D; Pollock R; O'Donnell P; Tirabosco R; Flanagan AM
    Mod Pathol; 2012 Oct; 25(10):1384-96. PubMed ID: 22699518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma.
    Erickson-Johnson MR; Seys AR; Roth CW; King AA; Hulshizer RL; Wang X; Asmann YW; Lloyd RV; Jacob EK; Oliveira AM
    Mod Pathol; 2009 Dec; 22(12):1541-7. PubMed ID: 19820690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical value of fluorescence
    Wang W; Li X; Liu P; Dong Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):228-233. PubMed ID: 37042132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysplastic lipoma: potential diagnostic pitfall of using MDM2 RNA in situ hybridization to distinguish between lipoma and atypical lipomatous tumor.
    Hung YP; Michal M; Dubuc AM; Rosenberg AE; Nielsen GP
    Hum Pathol; 2020 Jul; 101():53-57. PubMed ID: 32439322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics.
    Kimura H; Dobashi Y; Nojima T; Nakamura H; Yamamoto N; Tsuchiya H; Ikeda H; Sawada-Kitamura S; Oyama T; Ooi A
    Int J Clin Exp Pathol; 2013; 6(7):1306-16. PubMed ID: 23826411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silver In Situ Hybridization for the Rapid Assessment of MDM2 Amplification in Soft Tissue and Bone Tumors. Validation Based on an Audit of 192 Consecutive Cases Evaluated by Silver In Situ Hybridization and Fluorescence In Situ Hybridization.
    Farshid G; Otto S; Collis M; Napper S; Nicola M
    Appl Immunohistochem Mol Morphol; 2023 Feb; 31(2):101-106. PubMed ID: 36692149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular testing for lipomatous tumors: critical analysis and test recommendations based on the analysis of 405 extremity-based tumors.
    Zhang H; Erickson-Johnson M; Wang X; Oliveira JL; Nascimento AG; Sim FH; Wenger DE; Zamolyi RQ; Pannain VL; Oliveira AM
    Am J Surg Pathol; 2010 Sep; 34(9):1304-11. PubMed ID: 20679883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential diagnosis of lipoma and atypical lipomatous tumor/well-differentiated liposarcoma by cytological analysis.
    Sugiyama K; Washimi K; Sato S; Hiruma T; Sakai M; Okubo Y; Miyagi Y; Yokose T
    Diagn Cytopathol; 2022 Mar; 50(3):112-122. PubMed ID: 34984861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.
    Shimada S; Ishizawa T; Ishizawa K; Matsumura T; Hasegawa T; Hirose T
    Hum Pathol; 2006 Sep; 37(9):1123-9. PubMed ID: 16938516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical lipomatous tumor/well differentiated liposarcoma and related mimics with updates. When is molecular testing most cost-effective, necessary, and indicated?
    Kilpatrick SE
    Hum Pathol; 2024 May; 147():82-91. PubMed ID: 38135062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma.
    Weaver J; Goldblum JR; Turner S; Tubbs RR; Wang WL; Lazar AJ; Rubin BP
    Mod Pathol; 2009 Jan; 22(1):66-70. PubMed ID: 18836421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons learnt from MDM2 fluorescence in-situ hybridisation analysis of 439 mature lipomatous lesions with an emphasis on atypical lipomatous tumour/well-differentiated liposarcoma lacking cytological atypia.
    Vargas AC; Joy C; Cheah AL; Jones M; Bonar F; Brookwell R; Garrone B; Talbot J; Harraway J; Gill AJ; Maclean FM
    Histopathology; 2022 Jan; 80(2):369-380. PubMed ID: 34523152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of
    Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S
    Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
    Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
    Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FISH Diagnostic Assessment of
    Gambella A; Bertero L; Rondón-Lagos M; Verdun Di Cantogno L; Rangel N; Pitino C; Ricci AA; Mangherini L; Castellano I; Cassoni P
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674856
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.